Results 91 to 100 of about 1,600,619 (301)

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

open access: yesMolecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto   +13 more
wiley   +1 more source

Las mujeres en la prensa de la segunda mitad del siglo XIX: redes de colaboración

open access: yesPasado y Memoria
Las características específicas del ejercicio del periodismo en el siglo XIX hicieron que la construcción de su profesionalización presentase elementos diferenciadores respecto a otras profesiones como la abogacía, la medicina o la ingeniería.
Carolina Pecharroman de la Cruz
doaj   +1 more source

Interpretaciones del héroe clásico: la genealogía de la idea de noble/honrado y su desarrollo en la tratadística nobiliaria luso-castellana (1556-1640). Algunos ejemplos

open access: yesÁgora, 2011
El artículo busca reflexionar sobre la relación entre el mundo clásico y el concepto de noble en la tratadística nobiliaria luso‐castellana de la primera Edad Moderna, analizando el papel y la influencia de autores como Aristóteles o Cicerón y su ...
José Antonio Guillén Berrendero
doaj   +1 more source

Effect of chemotherapy on passenger mutations in metastatic colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Changes in passenger mutation load and predicted immunotherapy response after chemotherapy treatment. Tumor cells rich with passenger mutations have increased sensitivity to chemotherapy. Correlation of passenger mutations with neoantigen load suggests highly mutated clones promote a more effective response to immunotherapy, and therefore, first‐line ...
Marium T. Siddiqui   +6 more
wiley   +1 more source

Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells

open access: yesMolecular Oncology, EarlyView.
Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son   +13 more
wiley   +1 more source

Identidad de género y honor en los sectores populares de Cali colonial

open access: yesHistoria y Espacio, 2008
El objetivo del presente artículo es explicar la formación de las identidades de género en los sectores populares1, a partir de la asimilación y resistencia al Código de Honor y género predominante en Cali a finales del período colonial.
Lida Elena Tascón Bejarano
doaj   +1 more source

Whalesong [PDF]

open access: yes, 1988
Ballot decision upsets Regents -- UAS Library bids opened -- UAS logo selection questioned -- Knight greets year -- A Whaler welcome -- Enrollment up by 53 -- New page opens at bookstore -- Spring honor rolls announced -- NEWS ...

core  

Some remarks on the work of Lawrence Ein

open access: yes, 2017
This is a write-up of introductory remarks that I made at the UIC conference in honor of Lawrence Ein's 60th birthday.
Lazarsfeld, Robert
core   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

open access: yesMolecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck   +12 more
wiley   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

open access: yesMolecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy